Showing results (151-160 of 162) with videos related to
Sort By:
Pageof 17
Cancer Research|May 9, 2018
Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor StageTamara Aleksic, Nicki Gray, Xiaoning Wu, et al.Oncoimmunology|February 1, 2020
Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapyJoseph P Sanderson, Darragh J Crowley, Guy E Wiedermann, et al.Cancers|June 13, 2025
LMP7-Specific Inhibitor M3258 Modulates the Tumor Microenvironment of Triple-Negative Breast Cancer and Inflammatory Breast CancerXuemei Xie, Jangsoon Lee, Ganiraju C Manyam, et al.Molecular Cancer Therapeutics|February 7, 2020
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor SurveillanceMarco H Hofmann, Rajeswaran Mani, Harald Engelhardt, et al.Frontiers in Oncology|April 4, 2022
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial TumorsDavid S Hong, Marcus O Butler, Russell K Pachynski, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2023
Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8αVictoria E Anderson, Sara S Brilha, Anika M Weber, et al.Journal for Immunotherapy of Cancer|January 28, 2022
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancerGeorge R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, et al.Plos One|October 16, 2018
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) moleculesJane Harper, Katherine J Adams, Giovanna Bossi, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 2, 2021
Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-βJonathan D Silk, Rachel J M Abbott, Katherine J Adams, et al.Molecular Therapy. Methods & Clinical Development|June 14, 2024
Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patientsTianjiao Wang, Jean-Marc Navenot, Stavros Rafail, et al.Pageof 17